Comparer des méthodes

	Échelle de Qualité de Vie dans la Polyarthrite Psoriasique (PsAQoL)	Indice d'activité de la spondylarthrite ankylosante de Bath (BASDAI)
Domaine	Rhumatologie	Rhumatologie
Famille	Process / pipeline	Process / pipeline
Année d'origine	1997	1994
Auteur d'origine	McKenna & Doherty	Garrett et al.
Type	Patient-reported outcome (PRO)	Patient-reported outcome (PRO)
Source fondatrice	Soderlin MK, Bergman S. Psychometric properties of the Psoriatic Arthritis Quality of Life (PsAQoL) instrument: Rasch analysis. Arthritis Care Research. 2011;63(11):1589-1595.	Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. The Journal of Rheumatology. 1994;21(12):2286-2291.
Alias	PsAQoL, PSAQoL	BASDAI, BAS-DAI
Apparentées	4	4
Résumé	The PsAQoL is a disease-specific patient-reported outcome measure of quality of life impact in psoriatic arthritis (PsA), a chronic inflammatory condition affecting joints and skin. Developed by McKenna and Doherty in 1997, PsAQoL comprises 20 items assessing the multidimensional impact of PsA on physical function, emotional well-being, work productivity, and social participation. PsAQoL captures the patient's lived experience of the disease, complementing clinical disease activity measures (CRP, joint counts) and providing a holistic view of treatment benefit in PsA research and practice.	The BASDAI is a patient-reported outcome measure of disease activity in ankylosing spondylitis (AS), a chronic inflammatory arthropathy affecting the spine and axial skeleton. Introduced by Garrett et al. in 1994, BASDAI uses six simple patient self-report items focused on the cardinal symptoms of AS: fatigue, spinal pain, peripheral joint involvement, and morning stiffness. As a PRO measure, BASDAI is practical for routine monitoring, responsive to treatment, and strongly associated with clinical outcomes and spinal damage progression, making it a cornerstone outcome in AS management and clinical trials.